WALTHAM,
Mass., Dec. 14, 2022 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical-stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced the
closing of its previously announced underwritten public offering of
7,840,909 shares of its common stock at a price to the public of
$22.00 per share. This includes the
exercise in full by the underwriters of their option to purchase up
to 1,022,727 additional shares of common stock. The aggregate gross
proceeds to Syndax from this offering were $172.5 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Syndax. Following the closing of the Offering, Syndax has
68,100,918 shares issued and outstanding as of December 14, 2022.
Goldman Sachs & Co. LLC, J.P. Morgan and Cowen acted as
joint book-running managers for the offering. BTIG and B. Riley
Securities acted as co-lead managers for the offering.
The shares were offered pursuant to a "shelf" registration
statement previously filed and declared effective by the Securities
and Exchange Commission (SEC). A final prospectus supplement and
accompanying prospectus relating to the offering were filed with
the SEC and are available on the SEC's website located at
http://www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus relating to the offering may be obtained
from: Goldman Sachs and Co. LLC, Attention: Prospectus Department,
200 West Street, New York, NY
10282, telephone: 866-471-2526, facsimile: 212-902-9316 or by
emailing Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone:
(866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; or
Cowen and Company, LLC, c/o Broadridge Financial Solutions,
Attention: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib (SNDX-5613), a highly selective inhibitor of the
Menin–MLL binding interaction, and axatilimab, a monoclonal
antibody that blocks the colony stimulating factor 1 (CSF-1)
receptor, both currently in pivotal trials.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Factors that may cause Syndax's actual results to
differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Syndax's filings
with the U.S. Securities and Exchange Commission, including the
"Risk Factors" sections contained therein, as well as the risks
identified in the registration statement and the preliminary
prospectus supplement relating to the offering. These
forward-looking statements are based on Syndax's expectations and
assumptions as of the date of this press release. Except as
required by law, Syndax assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301703390.html
SOURCE Syndax Pharmaceuticals, Inc.